{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T14:25:13Z","timestamp":1794925513380,"version":"4.9.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Antibodies to MuSK identify a rare subtype of myasthenia gravis (MuSK-MG). In western countries, the onset age of MuSK-MG peaks in the late 30's while it is unknown in Chinese population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective multicenter study, we screened 69 MuSK-MG patients from 2042 MG patients in five tertiary referral centers in China from October 2016 to October 2021 and summarized the clinical features and treatment outcomes. Then we subgrouped the patients into early-onset (&amp;lt;50 years old), late-onset (50\u201364 years old), and very-late-onset (\u226565 years old) MG and compared the differences in weakness distribution, disease progression and treatment outcomes among three subgroups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The patients with MuSK-MG were female-dominant (55\/69) and their mean age at onset was 44.70 \u00b1 15.84 years old, with a broad range of 17\u201381 years old. At disease onset, 29\/69 patients were classified as MGFA Type IIb and the frequency of bulbar and extraocular involvement was 53.6 and 69.6%, respectively. There was no difference in weakness distribution. Compared with early-onset MuSK-MG, very-late-onset patients had a higher proportion of limb muscle involvement (12\/15 vs.16\/40, <jats:italic>p<\/jats:italic> = 0.022) 3 months after onset. Six months after onset, more patients with bulbar (14\/15 vs. 26\/39, <jats:italic>p<\/jats:italic> = 0.044) and respiratory involvement (6\/15 vs. 0\/13, <jats:italic>p<\/jats:italic> = 0.013) were seen in very-late-onset than in late-onset subgroup. The very-late-onset subgroup had the highest frequency of limb weakness (86.7%, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). One year after onset, very-late-onset patients demonstrated a higher frequency of respiratory involvement than early-onset patients (4\/12 vs. 2\/35, <jats:italic>p<\/jats:italic> = 0.036). 39\/64 patients reached MSE. Among 46 patients who received rituximab, very-late-onset patients started earlier than late-onset patients [6 (5.5\u20137.5) vs. 18 (12\u201365) months, <jats:italic>p<\/jats:italic> = 0.039], but no difference in the time and rate to achieving MSE was identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MuSK-MG patients usually manifested as acute onset and predominant bulbar and respiratory involvement with female dominance. Very-late-onset patients displayed an early involvement of limb, bulbar and respiratory muscles in the disease course, which might prompt their earlier use of rituximab. The majority MuSK-MG patients can benefit from rituximab treatment regardless of age at onset.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.879261","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T07:23:42Z","timestamp":1649402622000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical Features of Myasthenia Gravis With Antibodies to MuSK Based on Age at Onset: A Multicenter Retrospective Study in China"],"prefix":"10.3389","volume":"13","author":[{"given":"Yufan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Huan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenshuang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3988\/jcn.2009.5.2.53","article-title":"Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status","volume":"5","author":"Oh","year":"2009","journal-title":"J Clin Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1196\/annals.1405.005","article-title":"Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis","volume":"1132","author":"Wolfe","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/01.wco.0000180660.57801.3f","article-title":"Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis","volume":"18","author":"Vincent","year":"2005","journal-title":"Curr Opin Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1749-6632.2012.06781.x","article-title":"Management challenges in muscle-specific tyrosine kinase myasthenia gravis","volume":"1274","author":"Evoli","year":"2012","journal-title":"Ann N Y Acad Sci."},{"key":"B6","unstructured":"Clinical characteristics of refractory myasthenia gravis patients25560\n            SuhJ\n            GoldsteinJM\n            NowakRJ\n          23766745Yale J Biol Med.862013"},{"key":"B7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11910-016-0668-z","article-title":"Muscle-specific receptor tyrosine kinase (MuSK) myasthenia gravis","volume":"16","author":"Hurst","year":"2016","journal-title":"Curr Neurol Neurosci Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1111\/ene.12169","article-title":"Thymus histology and concomitant autoimmune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis","volume":"20","author":"Nakata","year":"2013","journal-title":"Eur J Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cort\u00e9s-Vicente","year":"2020","journal-title":"Neurology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1007\/s10072-021-05599-z","article-title":"Characteristics of myasthenia gravis in elderly patients: a retrospective study","volume":"43","author":"Li","year":"2021","journal-title":"Neurol Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1111\/j.1532-5415.2000.tb02635.x","article-title":"Clinical characteristics and prognosis of myasthenia gravis in older people","volume":"48","author":"Evoli","year":"2000","journal-title":"J Am Geriatr Soc."},{"key":"B13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3760\/cma.j.issn.0578-1426.2011.06.013","article-title":"[The clinical characteristics of early-onset versus late-onset types of myasthenia gravis]","volume":"50","author":"Wang","year":"2011","journal-title":"Zhonghua nei ke za zhi."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1007\/s00415-012-6478-6","article-title":"Characteristics of late-onset myasthenia gravis","volume":"259","author":"Zivkovi\u0107","year":"2012","journal-title":"J Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1136\/jnnp.2004.052415","article-title":"The features of myasthenia gravis with autoantibodies to MuSK","volume":"76","author":"Lavrnic","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41582-020-0345-3","article-title":"New insights into very-late-onset myasthenia gravis","volume":"16","author":"Barnett","year":"2020","journal-title":"Nat Rev Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/s0003-4975(00)01595-2","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"70","author":"Jaretzki","year":"2000","journal-title":"Ann Thorac Surg."},{"key":"B18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.4065\/73.11.1077","article-title":"Myasthenia gravis mimicking stroke in elderly patients","volume":"73","author":"Kleiner-Fisman","year":"1998","journal-title":"Mayo Clin Proc."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","article-title":"Clinical aspects of MuSK antibody positive seronegative MG","volume":"60","author":"Sanders","year":"2003","journal-title":"Neurology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12883-021-02439-7","article-title":"Clinical features, treatment and prognosis of MuSK antibody-associated myasthenia gravis in Northwest China: a single-centre retrospective cohort study","volume":"21","author":"Zhao","year":"2021","journal-title":"BMC Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1136\/jnnp.74.8.1105","article-title":"Evidence of underdiagnosis of myasthenia gravis in older people","volume":"74","author":"Vincent","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1196\/annals.1405.040","article-title":"Myasthenia gravis in the elderly: is it different?","volume":"1132","author":"Aarli","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1159\/000478012","article-title":"Autoimmunity in the elderly: insights from basic science and clinics - a mini-review","volume":"63","author":"Watad","year":"2017","journal-title":"Gerontology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/nyas.13519","article-title":"Thymus involvement in early-onset myasthenia gravis","volume":"1412","author":"Cron","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/archneur.56.1.25","article-title":"Late-onset myasthenia gravis: a changing scene","volume":"56","author":"Aarli","year":"1999","journal-title":"Arch Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1212\/WNL.40.5.786","article-title":"The relationship of age to outcome in myasthenia gravis","volume":"40","author":"Donaldson","year":"1990","journal-title":"Neurology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2353\/ajpath.2007.070240","article-title":"Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status","volume":"171","author":"Leite","year":"2007","journal-title":"Am J Pathol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00281-021-00842-3","article-title":"Thymus and autoimmunity","volume":"43","author":"Marx","year":"2021","journal-title":"Semin Immunopathol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1474-4422(21)00357-4","article-title":"Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders","volume":"21","author":"Huijbers","year":"2022","journal-title":"Lancet Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3324\/haematol.2009.018689","article-title":"Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells","volume":"95","author":"Caraux","year":"2010","journal-title":"Haematologica."},{"key":"B33","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1002\/cyto.b.20547","article-title":"Human peripheral blood B-cell compartments: a crossroad in B-cell traffic","volume":"78","author":"Perez-Andres","year":"2010","journal-title":"Cytom Part B Clin Cytom."},{"key":"B34","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1365-2249.2010.04206.x","article-title":"Reference values for B cell subpopulations from infancy to adulthood","volume":"162","author":"Morbach","year":"2010","journal-title":"Clin Exp Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00401-017-1754-2","article-title":"Muscle satellite cells are functionally impaired in myasthenia gravis: consequences on muscle regeneration","volume":"134","author":"Attia","year":"2017","journal-title":"Acta Neuropathol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.celrep.2015.09.067","article-title":"Age-associated methylation suppresses SPRY1, leading to a failure of re-quiescence and loss of the reserve stem cell pool in elderly muscle","volume":"13","author":"Bigot","year":"2015","journal-title":"Cell Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11357-013-9583-2","article-title":"Satellite cells in human skeletal muscle; from birth to old age","volume":"36","author":"Verdijk","year":"2014","journal-title":"Age."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.879261\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T07:23:49Z","timestamp":1649402629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.879261\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":38,"alternative-id":["10.3389\/fneur.2022.879261"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.879261","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fneur.2022.879261.s001","asserted-by":"subject"}]},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,8]]},"article-number":"879261"}}